News

   

Oncoinvent ASA: Announces webcast presentation of second half 2025 results on Thursday 26 February 2026

Oslo, Norway, 16 February 2026: Oncoinvent ASA (ONCIN), a biotech…

AmacaThera Named Life Sciences Ontario Emerging Company of the Year

Recognition of AmacaThera’s leadership and landmark agreement…

Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results

· Strong Q4 with 76.0 MSEK in revenue, up 135% from Q4 2024. ·…

Hans Schambye Appointed as Chief Executive Officer of BOOST Pharma

Advancing development of lead candidate BT-101, a potential…

Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies

Financing led by Investissement Québec with continued support…

Biocomposites gains MDR certification for STIMULAN® Rapid Cure and STIMULAN® Kit

STIMULAN® certified to be mixed with a combination of Gram-positive…

Four additional sites open for recruitment in Oncoinvent’s Phase 2 trial

Oslo, Norway, 29 January 2026: Oncoinvent, a clinical stage,…

Biocomposites launches SYNICEM™ spacers in Canada

Ready-to-use preformed antibiotic loaded spacers for hip,…

ViCentra Appoints Diabetes Commercialization Leader Reman McDonagh as Vice President, Global Marketing

Marketing executive brings 20+ years of global diabetes experience…

Poolbeg Pharma plc – Peer-Reviewed POLB 001 LPS Challenge Trial Paper Published in Frontiers in Immunology

28 January 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the…

Hansa Biopharma to host Year-end report 2025 conference call

Lund, Sweden, 26 January, 2026. Hansa Biopharma, “Hansa”…

New global consortium aims to transform antibiotic discovery to counter the growing AMR crisis

Philanthropic partners invest US$60 million to support collaborative…

Resolve M Therapeutics exits from stealth

Unique platform designed to engage pro-resolution responses to…

Infinitopes Expands Seed Financing to $35 Million to Accelerate Clinical Development of Precision Cancer Vaccine

Financing co-led by Octopus Ventures and new investor Amplify…

Women in Life Science Denmark (WiLD) expands Nordic footprint with launch of WiLD Finland

WiLD strengthens Nordic collaboration across Denmark, Finland,…

AMSilk’s bioengineered silk protein yarns debut in Balenciaga Spring 2026 Collection

First commercially available products using AMSilk’s biotech…

Novo Nordisk Foundation grants DKK 5.5 billion to elevate innovation in Denmark and Europe

The Novo Nordisk Foundation has allocated up to DKK 5.5 billion…

AMS: Full Year 2025 Trading Update

~ Strong growth in line with expectations, driven by key surgical…

We’d love to hear from you.

For more information about Optimum Strategic Communications, please get in touch.

© Optimum Strategic Communications.